Link to the R&D update webinar (
The agenda for Herantis' R&D update webinar:
Welcome and Introduction |
Achivements during 2022 |
Why HER-096 is a perfect drug candidate for Parkinson's disease (PD) |
HER-096 animal data confirm its unique mechanism of action and brain penetration |
Update on CDNF |
Clinical development and biomarkers |
Strategy and development milestones for 2023 |
Closing Statement & Q&A |
About HER-096:
HER-096 is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein. HER-096 has demonstrated to have a multimodal mechanism of action mimicking CDNF and to improve functional recovery of damaged neurons in preclinical models. Importantly, HER-096 has been shown to readily penetrate the blood brain barrier in preclinical studies allowing convenient subcutaneous dosing. Thanks to its multimodal mechanism of action, Herantis' HER-096 has the potential to stop the progression of Parkinson's disease and significantly improve patients' quality of life.
R&D Update Webinar Information:
Please join Herantis' R&D update webinar on
After registering, you will receive a confirmation email containing information about joining the webinar. For more information and to access the live webcast, including audio, video and presentation slides, visit our web site at www.herantis.com .
The audience will have an opportunity to ask questions in a live Q&A session with speakers. Questions to event speakers may be asked beforehand by sending an e-mail to ir@herantis.com. During the event, questions may be asked by using the chat function on the live webcast dashboard as well as by emailing ir@herantis.com. Interested parties unable to watch the live webcast will be able to view and listen to an archived copy of the webcast, which will be available on www.herantis.com/investors/ following the conclusion of the event.
For more information, please contact:
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
Certified Advisor:
Company website: www.herantis.com
About
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. As previously announced by Herantis,
For more information, please visit www.herantis.com
https://news.cision.com/herantis-pharma-oyj/r/herantis-pharma-to-host-a-r-d-update-webinar-on-january-19--2023,c3696374
https://mb.cision.com/Main/18884/3696374/1775287.pdf
(c) 2023 Cision. All rights reserved., source